ACS Appl Mater Interfaces
November 2021
Eur Urol Oncol
April 2022
Background: Pembrolizumab plus axitinib improved efficacy over sunitinib in treatment-naive advanced renal cell carcinoma in the KEYNOTE-426 (NCT02853331) study. However, a relatively high incidence of grade 3/4 aminotransferase elevations was observed.
Objective: To further characterize treatment-emergent aminotransferase elevations in patients treated with pembrolizumab-axitinib.